drugset / Trial / NCT00002681
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
Phase 1/2
Completed
25 enrolled
Roger Williams Medical Center
Beth Israel Deaconess Medical Center · collabNational Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia or lymphoma cells. Combining these two therapies may be an effective treatment for leukemia and lymphoma. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy plus interleukin-2 in treating patients who have leukemia or lymphoma.
Timeline
- Start
- 1995-07
- Primary completion
- 2003-09
- Completion
- 2003-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclizumab | Monoclonal antibody | — | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |